The role of positron emission tomography in management of small cell lung cancer

D. Thomson; P. Hulse; P. Lorigan; C. Faivre-Finn

doi:10.1016/j.lungcan.2011.03.013

The role of positron emission tomography in management of small cell lung cancer

D. Thomson, P. Hulse, P. Lorigan, C. Faivre-Finn

Research output: Contribution to journal › Article › peer-review

Abstract

Accurate radiological staging of small-cell lung cancer (SCLC) is of paramount importance in selection of individual patients with limited stage disease for potentially curative treatment while avoiding toxic treatment in those with distant metastatic disease. [ 18F] flurodeoxy-d-glucose (FDG) positron emission tomography (PET) is an attractive tool for this purpose but there is limited evidence to support its use in the routine staging of SCLC. Whether therapeutic decisions based on FDG-PET imaging should be made remains uncertain. There is only preliminary evidence for use of FDG-PET as a prognostic biomarker, in the assessment of response to treatment and delineation of disease in conformal radiation planning. © 2011 Elsevier Ireland Ltd.

Original language	English
Pages (from-to)	121-126
Number of pages	5
Journal	Lung Cancer
Volume	73
Issue number	2
DOIs	https://doi.org/10.1016/j.lungcan.2011.03.013
Publication status	Published - Aug 2011

Keywords

FDG-PET
Lung cancer
PET
PET-CT
Positron emission tomography
Small-cell lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2011.03.013

Cite this

@article{c43afd7141044215b33d0767514e8c83,

title = "The role of positron emission tomography in management of small cell lung cancer",

abstract = "Accurate radiological staging of small-cell lung cancer (SCLC) is of paramount importance in selection of individual patients with limited stage disease for potentially curative treatment while avoiding toxic treatment in those with distant metastatic disease. [ 18F] flurodeoxy-d-glucose (FDG) positron emission tomography (PET) is an attractive tool for this purpose but there is limited evidence to support its use in the routine staging of SCLC. Whether therapeutic decisions based on FDG-PET imaging should be made remains uncertain. There is only preliminary evidence for use of FDG-PET as a prognostic biomarker, in the assessment of response to treatment and delineation of disease in conformal radiation planning. {\textcopyright} 2011 Elsevier Ireland Ltd.",

keywords = "FDG-PET, Lung cancer, PET, PET-CT, Positron emission tomography, Small-cell lung cancer",

author = "D. Thomson and P. Hulse and P. Lorigan and C. Faivre-Finn",

year = "2011",

month = aug,

doi = "10.1016/j.lungcan.2011.03.013",

language = "English",

volume = "73",

pages = "121--126",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - The role of positron emission tomography in management of small cell lung cancer

AU - Thomson, D.

AU - Hulse, P.

AU - Lorigan, P.

AU - Faivre-Finn, C.

PY - 2011/8

Y1 - 2011/8

N2 - Accurate radiological staging of small-cell lung cancer (SCLC) is of paramount importance in selection of individual patients with limited stage disease for potentially curative treatment while avoiding toxic treatment in those with distant metastatic disease. [ 18F] flurodeoxy-d-glucose (FDG) positron emission tomography (PET) is an attractive tool for this purpose but there is limited evidence to support its use in the routine staging of SCLC. Whether therapeutic decisions based on FDG-PET imaging should be made remains uncertain. There is only preliminary evidence for use of FDG-PET as a prognostic biomarker, in the assessment of response to treatment and delineation of disease in conformal radiation planning. © 2011 Elsevier Ireland Ltd.

AB - Accurate radiological staging of small-cell lung cancer (SCLC) is of paramount importance in selection of individual patients with limited stage disease for potentially curative treatment while avoiding toxic treatment in those with distant metastatic disease. [ 18F] flurodeoxy-d-glucose (FDG) positron emission tomography (PET) is an attractive tool for this purpose but there is limited evidence to support its use in the routine staging of SCLC. Whether therapeutic decisions based on FDG-PET imaging should be made remains uncertain. There is only preliminary evidence for use of FDG-PET as a prognostic biomarker, in the assessment of response to treatment and delineation of disease in conformal radiation planning. © 2011 Elsevier Ireland Ltd.

KW - FDG-PET

KW - Lung cancer

KW - PET

KW - PET-CT

KW - Positron emission tomography

KW - Small-cell lung cancer

U2 - 10.1016/j.lungcan.2011.03.013

DO - 10.1016/j.lungcan.2011.03.013

M3 - Article

C2 - 21524814

SN - 0169-5002

VL - 73

SP - 121

EP - 126

JO - Lung Cancer

JF - Lung Cancer

IS - 2

ER -

The role of positron emission tomography in management of small cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this